EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost-Utility of Dapagliflozin in CKD: Commendable Evidence and Pending Global Challenges

Pedro Cena Rivero

BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences · 22.07.2026

DOI: 10.70099/bj/2026.03.03.9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences, online erschienen am 22.07.2026. Verfasst von Pedro Cena Rivero. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent systematic review by Watema-Lord et al. concludes that dapagliflozin is a cost-effective intervention for managing chronic kidney disease (CKD) in high-income settings. This commentary critically appraises the review's findings, highlighting both its significant contributions to health economics and the limitations that restrict its global applicability. While the evidence robustly supports the clinical and economic benefits of dapagliflozin—backed by analyses of over 300 medical records—several critical gaps remain. The current economic models rely predominantly on a single clinical trial, introducing potential funding bias. Furthermore, the review underscores a pronounced lack of cost-utility data from low- and middle-income countries (LMICs), where out-of-pocket costs may render the therapy unaffordable despite its long-term benefits. Additionally, the absence of head-to-head economic comparisons with other SGLT2 inhibitors and the short period since CKD-specific approval introduce long-term uncertainties. To translate these promising results into equitable global health policy, future research must prioritize independent economic evaluations, head-to-head pharmacoeconomic comparisons, and models specifically tailored to healthcare systems in LMICs.

Zitieren

APA

Rivero, P. C. (2026). Cost-Utility of Dapagliflozin in CKD: Commendable Evidence and Pending Global Challenges. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. https://doi.org/10.70099/bj/2026.03.03.9

Vancouver

Rivero PC. Cost-Utility of Dapagliflozin in CKD: Commendable Evidence and Pending Global Challenges. BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences. 2026. doi:10.70099/bj/2026.03.03.9

BibTeX
@article{Rivero2026,
  author = {Rivero, Pedro Cena},
  title = {Cost-Utility of Dapagliflozin in CKD: Commendable Evidence and Pending Global Challenges},
  journal = {BioNatura Journal: Ibero-American Journal of Biotechnology and Life Sciences},
  year = {2026},
  doi = {10.70099/bj/2026.03.03.9}
}
Kostenlos starten →